• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Methyltransferase Assay Kits
      • Ligase and Synthetase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • AMPK Assay Kits
      • cGAS Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • TBK1 Assay Kits
    • Recombinant cGAS Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • OAS1 Assay Services
  • Innate Immunity
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD39 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

BellBrook Labs Expands Drug Discovery Services Portfolio to Include Lead Discovery Services

by Bellbrook Labs / Wednesday, 22 February 2017 / Published in Company, News

Madison, WI, February 2017 – In response to an increasing demand for characterization and prioritization of compounds downstream of HTS or virtual screening, BellBrook Labs is expanding its Drug Discovery Services to include Lead Discovery in addition to Assay Development.  BellBrook will use its proprietary Transcreener® HTS assay platform to accelerate clients’ hit-to-lead and SAR programs with accurate, reliable data on inhibitor potency, selectivity, mechanism of action, and binding kinetics for enzyme drug targets including kinases, phosphodiesterases, methyltransferases, ligases/synthetases, ATPases, and GTPases.  

BellBrook Labs – Accelerating Drug Discovery

Accelerating the Drug Discovery Process Infographic with Bellbrook Labs

BellBrook Labs is formalizing a significant expansion of their Drug Discovery Services portfolio to include an array of biochemical analyses critical for Lead Discovery.  The company’s Lead Discovery Services will provide clients with reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor residence times on drug targets ranging from established candidates such as kinases and phosphodiesterases to emerging targets like methyltransferases, ligases/synthetases, ATPases, and GTPases.

BellBrook’s Transcreener® HTS assay platform is ideally suited for the detailed biochemical and kinetic analyses required for hit-to-lead programs.  Transcreener® is an extensively validated HTS platform that produces robust FP, TR-FRET and FI signals for nucleotides produced by enzymes; e.g. ADP for kinases. It has been used to screen tens of millions of wells over the last 10 years in pharma and biotech labs.

Because they use direct immunodetection of nucleotides, Transcreener® assays can provide more reliable results than alternative methods that rely on more complicated schemes involving coupling enzymes.  In addition, the ability to run Transcreener® assays in continuous mode enables analysis of inhibitor binding kinetics such as residence time, which is increasingly recognized as an important factor for drug efficacy.   Additional assay methods will be employed as needed to meet customer requirements.

Learn more about BellBrook’s Lead Discovery Services

Tagged under: Assay Development Services, drug discovery services, Lead Discovery Services

What you can read next

BellBrook Labs Develops a More Cost Effective Solution for Screening Phosphodiesterases, Ligases, and Synthetases
NEW! GTPase Assay with TR-FRET Readout
Transcreener Assays Highlighted for Novel Microbial and Epigenetic Targets at SLAS 2013

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Researcher Using An ADP Assay

    Accelerating Discovery of Kinase Inhibitors Using an ADP Assay

    An ADP assay can be used to study the activity ...
  • Inhibitors of ENPP1 SLAS Discovery

    New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1

    BellBrook scientist Meera Kumar and Robert Lowe...
  • GMP Assay for PDE Inhibitor Discovery

    Using a Universal GMP Assay for PDE Research

    A universal GMP assay to aid in PDE research an...
  • SLAS 2021

    Join Us for SLAS 2021 Virtual Conference

    BellBrook Labs will be exhibiting at SLAS 2021,...
  • New cGAS TR-FRET Assay

    New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

    Launched in November 2019, the Transcreener cGA...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2019 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP